Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 28, Issue 2, 1999, Pages 82-87

  Loro, Lado Lako ^a,b   Vintermyr, Olav Karsten ^a   Johannessen, Anne Christine ^a   Liavaag, Per Gunnar ^a   Jonsson, Roland ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Apoptosis; Fas; FasL; Oral squamous cell carcinoma

Indexed keywords

EID: 0033081325     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.1999.tb02001.x     Document Type: Article

References (34)

1. CARSON DA, RIBEIRO JM. Apoptosis and disease. Lancet 1993; 341: 1251-4.
2. WYLLIE AH. The genetic regulation of apoptosis. Curr Opin Genet Dev 1995; 5: 97-104.
3. KERR JF, WYLLIE AH, CURRIE AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
4. BEUTLER B, VAN HUFFEL C. Unraveling function of the TNF ligand and receptor families. Science 1994; 264: 667-8.
5. ITOH N, YONEHARA S, ISHII A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-43.
6. NAGATA S, GOLSTEIN P. The Fas death factor. Science 1995; 267: 1449-56.
7. NI R, TOMITA Y, MATSUDA K. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res 1994; 215: 332-7.
8. FLADMARK K, GJERTSEN B, DØSKELAND S, VINTERMYR O. Fas/APO-1 (CD 95)-induced apoptosis of primary hepatocytes is inhibited by cAMP. Biochem Biophy Res Commun 1997; 232: 20-5.
9. TRAUTH BC, KLAS C, PETERS AMJ, et al. Monoclonal antibody-mediated tumour regression by induction of apoptosis. Science 1989; 245: 301-5.
10. CHINNAIYAN AM, TEPPER CG, SELDIN MF, et al. FADD/MORT1 is a common mediator of CD 95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996; 271: 4961-5.
11. BOLDIN MP, GONCHAROV TM, GOLTSEV YV, WALLACH D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 1996; 85: 803-15.
12. ASHKENAZI A, DIXIT VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-8.
13. ADAMS JM, CORY S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6.
14. GREEN DR, REED JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
15. OLTVAI Z, MILLIMAN C, KORSMEYER SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
16. LEITHAUSER F, DHEIN J, MECHTERSHEIMER G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumour necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-29.
17. BENNET MW, O'CONNEL J, O'SULLIVAN GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-75.
18. GRATAS C, TOHMA Y, BARNAS C, TANIERE P, HAINUT P, OHGAKI H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998; 58: 2057-62.
19. MURAKI Y, YOSHIOKA C, FUKUDA J, HANEJI T, KOBAYASHI N. Immunohistochemical detection of Fas antigen in oral epithelia. J Oral Pathol Med 1997; 26: 57-62.
20. NAGATA S. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Lon Biol Sci 1994; 345: 281-7.
21. STRAND S, HOFMANN WJ, HUG H, et al. Lymphocyte apoptosis induced by CD 95 (APO-1/Fas) ligand-expressing tumour cells - a mechanism of immune evasion? Nat Med 1996; 2: 1361-6.
22. NAGATA S. Fas ligand and immune evasion. Nat Med 1996; 2: 1306-7.
23. HSU SM, RAINE L, FANGER H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-80.
24. GAVRIELI Y, SHERMAN Y, BEN-SASSON S. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
25. POTTEN CS. The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metastasis Rev 1992; 11: 179-95.
26. COLUMBANO A, LEDDA-COLUMBANO GM, RAO PM, RAJALAHSHMI S, SARMA DS. Occurrence of cell death (apoptosis) in preneoplastic and neoplastic liver cells. A sequential study. Am J Pathol 1984; 116: 441-6.
27. HINO N, HIGASHI T, NOUSO K, NAKATSUKASA H, TSUJI T. Apoptosis and proliferation of human hepatocellular carcinoma. Liver 1996; 16: 123-9.
28. BIRCHALL MA, WlNTERFORD CM, ALLAN DJ, HARMON BV. Apoptosis in normal epithelium, premalignant and malignant lesions of the oropharynx and oral cavity: a preliminary study. Eur J Cancer B Oral Oncol 1995; 31: 380-3.
29. SUNDELIN K, JADNER M, NORBERG-SPAAK L, DAVIDSSON Å, HELLQUIST HB. Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur J Cancer 1997; 33: 1860-4.
30. HELLQUIST HB, OLEJNICKA B, JADNER M, ANDERSSON T, SEDERHOLM C. Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoplosis are not pronounced: a preliminary report. Br J Cancer 1996; 76: 175-9.
31. IMAI A, HORIBE S, TAKAGI A, OIINO T, TAMAYA T. Frequent expression of Fas in gonadotropin-releasing hormone receptor-bearing tumors. Eur J Obstet Gynecol Reprod Biol 1997; 74: 73-8.
32. LIAVAAG PG, JOHANNESSEN AC, NILSEN R, JONSSON R. Analysis of T-cell receptor expressing lymphocytes infiltrating squamous cell carcinomas of the upper aerodigestive tract. Eur Arch Otorhinolaryngol 1994; 251: 452-6.
33. KAYAGAKI N, KAWASAKI A, ETABA T. et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777-83.
34. WALKFR PR, SAAS P, DIETRICH P. Role of Fas ligand (CD95L) in immune escape: the tumor strikes back. J Immunol 1997; 158: 4521-4.